ModifiedUnitedHealthcarePolicy CS009NE.V

Spinal Fusion and Bone Healing Enhancement Products (for Nebraska Only)

Clinical coverage and medical necessity determination for spinal fusion grafts and bone healing enhancement products for UnitedHealthcare members in Nebraska.

Policy Summary

PayerUnitedHealthcare

PolicySpinal Fusion and Bone Healing Enhancement Products (for Nebraska Only)

Policy CodePolicy CS009NE.V

Change TypeClarified coverage stancedefinitions and documentation language added

Effective DateDec 1, 2025

Next Review DateN/A

Key ActionProvide complete medical record documentation (history, exam, diagnostics) and prior authorization justification when requesting coverage, especially for products with limited evidence or off-label use.

SourceLink

POLICY UPDATE CHANGES

Added language to clarify Ceramic-Based Products (e.g., beta tricalcium phosphate, calcium phosphate, calcium sulfate) used alone or in combination with other grafts and/or graft components, including Bone Marrow Aspirate (BMA), are unproven and not medically necessary.

Added language about medical records documentation that may be required to assess whether the member meets clinical criteria for coverage and that documentation does not guarantee coverage.

Added definitions for osseointegration, osteoconduction, and osteoinduction; updated definitions for allograft, autograft, and bone marrow aspiration.

Updated Clinical Evidence, FDA, and References sections to reflect the most current information.

Autograft/DBM/AllograftProven items

Ceramics, amniotic, cell-basedUnproven/not medically necessary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

0814T,20930...Codes referenced

Limited/lowEvidence quality

Coverage Criteria and Policy Stance

inv-01: Covered when ALL criteria met

The following products and indications are considered proven and medically necessary when ALL criteria are met:

Proven/Medically Necessary items: Autografts (including Bone Marrow Aspirate [BMA])

Autograft (ICBG) is the historical gold standard and is listed as proven in policy

Proven/Medically Necessary items: Demineralized Bone Matrix (DBM) when not combined with products listed as unproven

DBM is listed as proven when not combined with unproven additives

Proven/Medically Necessary items: Allograft-based products not specifically listed as unproven in policy

Allograft products that are not on the unproven list are considered proven when appropriate

InFUSE (rhBMP-2) lumbar fusion

Approach is anterior or oblique and used in conjunction with an FDA‑approved interbody fusion device
Source specifies approach and device requirement
Patient is skeletally mature (≥18 years or radiographic evidence of epiphyseal closure) with degenerative disc disease (DDD)
Age/radiographic maturity and diagnosis requirement
Fusion involves vertebral bodies L2–S1 with spondylolisthesis ≤ grade 1 (≤25% displacement) at the involved level
Level and spondylolisthesis threshold provided in policy
Fusion is single‑level
Policy limits coverage to single‑level fusions for Infuse

InFUSE/MASTERGRAFT Posterolateral Revision Device System

Implanted via a posterolateral approach
Surgical approach requirement from policy
Presence of symptomatic posterolateral lumbar pseudoarthrosis
Indication requirement
Skeletally mature patient (older than 21 years or radiographic evidence of epiphyseal closure)
Age/radiographic maturity requirement distinct from Infuse lumbar indication
Autologous bone and/or bone marrow harvest is not feasible or is not expected to promote fusion
Requirement that autograft is not feasible or unlikely to succeed

Operational note: Coverage of the above products requires documentation in the medical record to support the requested service and the specific criteria (e.g., surgical approach, levels treated, imaging evidence). Documentation does not guarantee coverage and is governed by federal/state/contractual requirements.

See policy instructions for documentation requirements

inv-02: Not medically necessary / Unproven

The following products and indications are considered unproven and not medically necessary due to insufficient evidence of efficacy and/or safety:

Allograft-based cell and biologic products: Allograft-based cell-based products (e.g., mesenchymal stem cell [MSC] products) are considered unproven and not medically necessary

Listed explicitly as unproven in policy

Human amniotic tissue materials, including amniotic fluid stem cell substitutes and related amniotic products, are unproven and not medically necessary

Limited human evidence and unknown long‑term safety (policy and evidence summary)

Off‑label rhBMP‑2 and InFUSE/MASTERGRAFT uses: Recombinant human bone morphogenetic protein‑2 (e.g., InFUSE) and InFUSE/MASTERGRAFT for indications not listed as covered (including off‑label cervical use) are unproven and not medically necessary

Policy excludes uses other than specified lumbar and specific posterolateral revision indications; cervical use associated with safety concerns

inv-03: Product-class coverage logic

Coverage considerations vary by product class and indication. Summarized logical stances from the evidence in this section:

rhBMP‑2 (Infuse) — lumbar use: rhBMP‑2 (InFUSE) demonstrates comparable or higher fusion rates for lumbar interbody fusion (L2–S1) and is FDA‑approved for this indication; supported by systematic reviews and RCTs when used per FDA labelingFDA‑approved L2–S1 use with supporting trials

Evidence base includes RCTs and systematic reviews

rhBMP‑2 — cervical/off‑label: Use in the cervical spine is associated with higher rates of adverse events and FDA warnings; off‑label cervical use requires strong justification and risk mitigationStrong justification required for off‑label use

ECRI and FDA safety concerns noted

Human amniotic tissue products have limited clinical evidence in lumbar fusion and unknown long‑term safety; routine coverage is not supported without further research

inv-04: Coverage considerations and evidence thresholds

Coverage considerations informed by available evidence:

Preferred standard and evidence requirement: Preference for established graft materials (autograft/ICBG) or products supported by high‑quality randomized controlled trial (RCT) data; newer substitutes or device‑specific implants should have adequate randomized or well‑designed comparative trial evidence to support routine coverageHigh‑quality comparative evidence preferred

Derived from ECRI conclusions and repeated calls for larger RCTs

Products with some supportive evidence: Certain ceramic substitutes and synthetics (e.g., AttraX Putty, SiCaP, selected CBGS) have randomized or comparative data showing similar fusion rates to autograft in specific settings (PLF, XLIF) with reported fusion rates varying by product and timepointProduct‑specific trial evidence required

Evidence exists but is heterogeneous; consider on a case‑by‑case basis

Products lacking robust evidence:

inv-05: Guideline-based covered options (AANS/NASS)

Guideline-based coverage options and indications (per AANS and NASS statements):

DBM and b‑TCP recommendations (AANS): DBM may be used as a bone graft extender for 1‑ and 2‑level instrumented posterolateral fusions; b‑TCP/local autograft may be considered as a substitute for anterior iliac crest bone (AICB) for single‑level instrumented PLF

AANS guideline (Kaiser et al., 2014) supports these roles

Interbody fusion recommendations (NASS): Substitutes for AICB in ALIF with threaded cages or single‑level PLIF may be options due to similar fusion rates; DBM can be considered as a bone graft extender for TLIF with a structural interbody graft; evidence insufficient for routine rhBMP‑2 supplementation in certain standalone ALIF/TLIF scenarios

NASS statements on interbody fusion substitutes and rhBMP‑2 limitations

rhBMP‑2 (NASS guidance): rhBMP‑2 may be considered for ALIF, PLIF/TLIF, and posterolateral fusion in patients at high risk for nonunion or with inadequate autograft; should not be used routinely for anterior/posterior cervical fusions or single‑level posterior/posterolateral fusions in healthy adults

inv-06: Expandable interbody fusion systems — evidence and limits

Evidence summary on expandable interbody fusion systems:

Radiographic outcomes: Meta‑analysis and retrospective studies report that expandable cages increase anterior disc height and segmental lordosis, and some series show improved foraminal height up to 2 years

Radiographic gains reported in meta‑analysis and cohort studies

Clinical outcomes: Systematic review/meta‑analysis found no differences between expandable and static cages in posterior disc height, lumbar lordosis, subsidence rate, back or leg pain, or ODI; retrospective series report improved PROMs but are limited by design

No clear clinical benefit established; existing studies are low level

Evidence quality: Available evidence for expandable interbody systems is low quality (predominantly retrospective, single‑center series); lack of RCTs and heterogeneous follow‑up limit conclusions and preclude routine coverage as superiorLow quality evidence — RCTs needed

inv-07: Not medically necessary: Ceramic-based products with/without BMA

Policy-level coverage stance updates and explicit limits:

Ceramic-based products with/without BMA — policy stance: Ceramic‑Based Products (e.g., beta‑tricalcium phosphate [b‑TCP], calcium phosphate, calcium sulfate) used alone or in combination with other grafts and/or graft components, including Bone Marrow Aspirate (BMA), are considered unproven and not medically necessary.

This clarification was added to the coverage rationale effective 12/01/2025

Operational/documentation note: Medical records must document clinical indications, levels treated, imaging, and reasons why alternatives (e.g., autograft) are inappropriate when requesting coverage for products near policy limits; documentation does not guarantee coverage and is governed by federal/state/contractual requirements

Policy history specifies added documentation and governance language

Use of rhBMP-2 (InFUSE) and the InFUSE/MASTERGRAFT Posterolateral Revision Device for indications other than those explicitly listed as covered is considered unproven and not medically necessary. The policy lists rhBMP-2/InFUSE and the InFUSE/MASTERGRAFT device among products and indications that lack sufficient evidence of safety and efficacy when used outside approved or specified indications and therefore are excluded from routine coverage.

Use of rhBMP-2 for cervical fusion (off-label) is associated with serious, including life‑threatening, adverse events (for example, airway compression and neurologic compromise) and has been the subject of FDA warnings. NASS guidance and multiple evidence reviews note higher rates of adverse events with cervical use; therefore off‑label cervical application is effectively excluded from routine favorable coverage and requires strong clinical justification and risk mitigation if considered.

Products that lack published clinical data—including certain human amniotic tissue products and some ceramic substitutes with no comparative studies—are considered to have insufficient evidence for routine coverage. The policy identifies limited human data for amniotic tissue in lumbar fusion and notes that many ceramic-based products vary in composition and lack high-quality trials; absent supportive comparative evidence, these products are excluded from routine coverage.

Products without adequate, high-quality comparative evidence—such as many cell-based allografts and other emerging biologics—may effectively be excluded from standard coverage. Multiple evidence assessments found available studies to be very low quality (small, retrospective, single‑center, or industry‑sponsored), and concluded that well‑designed randomized controlled trials are needed before routine coverage can be supported.

Clinical society guidance (NASS/AANS) advises against the routine use of rhBMP-2 for anterior and posterior cervical fusion procedures and cautions about routine single‑level posterior/posterolateral use in healthy adults. These guideline statements, together with evidence of unique complications associated with rhBMP-2, inform the policy's restrictive stance on routine cervical and other off‑label indications.

The policy designates ceramic-based products (for example, beta tricalcium phosphate, calcium phosphate, calcium sulfate) used alone or in combination with other grafts or graft components—including Bone Marrow Aspirate (BMA)—as unproven and not medically necessary. Heterogeneity in composition and lack of consistent, high‑quality comparative trials prevent broad conclusions of equivalence to autograft, so routine coverage is not supported.

Human amniotic tissue membrane products and related amniotic tissue materials are considered unproven and not medically necessary for spinal fusion because current peer‑reviewed clinical evidence is limited, long‑term safety and efficacy are not established, and higher‑quality trials are needed before routine coverage is appropriate.

Allograft-derived cell-based products (for example, cellular bone allografts such as Trinity Elite, OsteoAMP, Bio4, PrimaGen, and similar products) are considered unproven and not medically necessary. Multiple ECRI and HTA assessments report very‑low‑quality evidence, limited comparative data, and high risk of bias in existing studies; therefore these products lack sufficient evidence to support routine coverage.

Routine use of human amniotic tissue for lumbar fusion is not supported by current evidence and is therefore considered not medically necessary until additional high‑quality data establish safety and effectiveness. The policy highlights limited human studies and the need for future research before routine authorization.

Expandable interbody fusion systems are described as unproven due to a lack of prospective randomized controlled trials with larger sample sizes and longer‑term follow‑up. Systematic reviews and meta-analyses report radiographic gains for some parameters but no clear clinical benefit versus static cages; given the low level of evidence, routine coverage is not supported without higher‑quality data.

Available evidence does not demonstrate a consistent clinical advantage of expandable cages over static systems. Meta-analysis and retrospective series report improvements in some radiographic measures (for example, anterior disc height and segmental lordosis) but found no differences in pain, ODI, or subsidence rates overall; the studies are limited by retrospective design and heterogeneity, and therefore no clear clinical benefit is established.

Ceramic‑based products (such as b‑TCP, calcium phosphate, calcium sulfate) when used alone or combined with other grafts/components including BMA are designated unproven and not medically necessary. The policy notes substantial variability among products and insufficient high‑quality comparative data to support routine coverage.

Applicable Procedure and Device Codes

Applicable procedure codes referencedCPT

0814T	Percutaneous injection of calcium-based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral.
20930	Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure).
20931	Allograft, structural, for spine surgery only (List separately in addition to code for primary procedure).
20939	Bone marrow aspiration for bone grafting, spine surgery only, through separate skin or fascial incision (List separately in addition to code for primary procedure).
22899	Unlisted procedure, spine

Device/approved product references (informational)mixed

OptiMesh	OptiMesh® Expandable Interbody Fusion System (FDA 510(k) K014200; de novo expanded indications).
Duo	Duo™ Expandable Interbody Fusion System (FDA 510(k) K210155 for one or two contiguous lumbar levels L2-L5).
InFUSE	InFUSE™ Bone Graft/LT-CAGE™ (FDA PMA P000058; multiple supplements and HDE for InFUSE/MASTERGRAFT).
i-FACTOR	i-FACTOR® peptide enhanced bone graft (FDA PMA referenced).

Prior Authorization, Documentation, and Provider Guidance

Prior Authorization

Prior authorization and coding

Prior authorization is required for many bone graft products and procedures. Coverage of specific products (including rhBMP-2/Infuse, InFUSE/MASTERGRAFT, novel implants, and certain ceramic or bioactive glass substitutes) is governed by the policy’s clinical criteria and applicable benefit rules. Coding and submitted documentation should accurately reflect the product used, indication, anatomic levels, and approach.

Submit specific product name and manufacturer when requesting prior authorization
Include procedure codes and device codes where applicable (see Applicable Codes)

Prior Authorization

Prior authorization for rhBMP-2 and off-label use

Requests to use rhBMP-2 (Infuse) — or any BMP product — must meet the policy’s lumbar-specific criteria. Off‑label uses (especially cervical fusion) require strong clinical justification and carry higher safety concerns; documentation must cite rationale and supporting evidence. Anticipate additional review or denial for off‑label cervical use due to FDA warnings about life‑threatening adverse events.

Infuse/ rhBMP-2 lumbar coverage limited to L2–S1, single‑level, anterior/oblique approach with an FDA‑approved interbody device

Clinical Background and Context

Autologous iliac crest bone graft (ICBG) remains the historical gold standard for spinal fusion because it provides osteoconductive, osteoinductive, and osteogenic properties. The policy recognizes ICBG's efficacy while noting donor‑site morbidity that motivates consideration of extenders or substitutes; however, alternatives require robust evidence to match ICBG's established performance.

Definitions

Allograft — definition

DefinitionTransplant of tissue from one individual to another of the same species with a different genotype; also known as an allogeneic graft or homograft.

SynonymsAllogeneic graft; homograft.

Typical usesUsed as morselized or structural graft material in spinal fusion procedures when autograft is unavailable or as an alternative to autograft.

NotesPolicy updates include clarified wording for allograft within definitions (effective 12/01/2025).

Autograft — definition

DefinitionTissue grafted into a new position in the body of the same individual.

Policy Summary

PayerUnitedHealthcare

PolicySpinal Fusion and Bone Healing Enhancement Products (for Nebraska Only)

Policy CodePolicy CS009NE.V

Change TypeClarified coverage stancedefinitions and documentation language added

Effective DateDec 1, 2025

Next Review DateN/A

SourceLink

On This Page

Ceramic-based products: Ceramic‑based products (e.g., beta‑tricalcium phosphate [b‑TCP], calcium phosphate, calcium sulfate) used alone or in combination with other grafts/components, including Bone Marrow Aspirate (BMA), are unproven and not medically necessary

Policy explicitly designates ceramic products alone or with BMA as unproven (material change)

Bioactive glass products used alone or in combination (including with BMA) are unproven and not medically necessary

Insufficient high‑quality evidence to establish efficacy/safety

Expandable interbody fusion systems are unproven and not medically necessary due to lack of prospective randomized trials with adequate size and follow‑up

Policy lists expandable interbody systems as unproven

Insufficient evidence

Policy cites need for future research

Ceramic‑based products: Evidence for ceramic products is heterogeneous—some trials (e.g., MagnetOs, AttraX Putty, SiCaP) report similar fusion rates to autograft in certain settings but methodological limitations and heterogeneity prevent broad conclusions; coverage should be product‑ and indication‑specific with direct supportive evidenceProduct‑specific high‑quality evidence preferred

Mixed results across RCTs, intra‑patient trials, and systematic reviews

Other osteobiologics (iFactor/ABM/P‑15, DBM, allograft): Some systematic reviews show acceptable fusion rates for products such as iFactor in lumbar procedures; use may be considered where supportive evidence for the specific indication existsIndication‑specific evidence

Limited and heterogeneous studies; consider when supportive evidence exists

Bioactive glass, many patient‑specific titanium implants, and expandable interbody systems currently lack sufficient high‑quality evidence (predominantly retrospective or small series); require additional RCTs or robust comparative data before routine coverage

Insufficient evidence — do not routinely cover

ECRI and systematic reviews highlight low quality of evidence

NASS guidance emphasizes selective use due to complication risks

Structural allograft indications: Structural cortical or corticocancellous allograft is indicated for anterior cervical reconstruction and other structural indications with or without additional autograft

NASS scope for structural allograft use

Policy recommends higher‑quality trials to support coverage decisions

Off‑label cervical use: include detailed justification and risk/benefit discussion; note FDA safety alerts

Note

Device FDA status (informational)

Device FDA clearance or approval is informational only. Providers should cite FDA status and indications for devices used (e.g., OptiMesh, Duo, InFUSE/MASTERGRAFT) when requesting coverage, but FDA listing alone does not guarantee coverage.

Provide FDA 510(k)/PMA/HDE identifiers or links when available
State whether the device is used within the FDA‑cleared indication

Prior Authorization

Prior authorization and benefit governance

Benefit coverage is determined by federal, state, and contractual requirements. Prior authorization requirements and final coverage determinations are governed by those requirements and applicable laws; the policy guides clinical review but does not supersede plan‑specific contractual rules.

Verify federal, state, or contract terms that may mandate coverage or impose additional restrictions
Prior authorization approval does not override plan exclusions or contractual limitations

Denial Risk

Medical record documentation and denial risk

Medical records must fully support medical necessity. Inadequate, missing, or illegible documentation may result in denial. Documentation should be complete, legible, and retrievable upon request.

Include relevant medical history, physical exam, and results of pertinent diagnostic tests or procedures
Ensure documentation demonstrates why the requested product is necessary versus standard alternatives

Denial Risk

Off‑label rhBMP-2 cervical use risk

Off‑label cervical use of rhBMP-2 carries elevated risk. The FDA has warned that Infuse use for cervical fusion can cause life‑threatening adverse events (e.g., airway or neurologic compression). Such requests may be subject to denial or require exhaustive justification and informed‑consent documentation.

If proposing cervical rhBMP-2, include explicit discussion of FDA warnings, alternative options tried or contraindicated, and documented informed consent

Denial Risk

Insufficient evidence products and risk

Products with insufficient or mixed evidence (e.g., many human amniotic tissue products, numerous ceramic formulations, bioactive glass variants, or novel implants like Aprevo) are frequently considered unproven. Requests for these products should include high‑quality comparative evidence showing clinical benefit for the planned indication.

Cite randomized trials, systematic reviews, or high‑quality comparative cohort studies when available
If evidence is limited to single‑arm or retrospective reports, expect additional review and higher risk of denial

Documentation Required

Fusion assessment and evidence documentation for ceramic products

When requesting coverage for ceramic‑based bone void fillers or bioactive glass products, include CT‑based fusion assessments and patient‑reported outcomes where available. Evidence cited should report fusion rates (1‑ and 2‑year CT assessments) and relevant clinical outcomes (ODI, VAS) to support effectiveness claims.

Include CT or radiographic fusion documentation at specified follow‑up intervals (e.g., 6, 12, 24 months when available)
Provide ODI, VAS, or other validated PROs to substantiate functional benefit

Documentation Required

Clinical evidence to support requests

Clinical evidence used to support requests should preferentially be high quality (RCTs, systematic reviews, well‑conducted comparative cohort studies). Single‑center retrospective series, small nonrandomized studies, or studies with very high risk of bias provide limited support and may not be sufficient for coverage of novel products.

Summarize study design, sample size, follow‑up duration, and outcomes when submitting evidence
Explain why cited evidence is applicable to the member’s clinical situation

Documentation Required

Medical records documentation requirements

Medical records must contain all information necessary to justify the requested service. Documentation may be requested during review, and absence of required records may lead to denial. Complete records do not guarantee coverage but are required for determination.

Maintain legible records of history, exam, imaging, prior treatments, and rationale for product selection
Be prepared to submit operative reports, device implant details, and postoperative follow‑up notes

Step Therapy

Stepwise use of graft materials and preference for autograft

When selecting graft materials, consider a stepwise approach favoring established options first. Autograft (e.g., iliac crest) is the preferred standard where feasible; extenders or substitutes (DBM, BMA, approved ceramics) should be considered based on comparative evidence and specific clinical circumstances.

Document why autograft is not feasible or is contraindicated if proposing substitutes
If proposing newer or device‑specific materials, document prior use or trial of established graft options when clinically appropriate

Considered the historical gold standard (e.g., iliac crest) for spinal fusion due to osteoconductive, osteoinductive, and osteogenic properties; used when highest fusion potential is desired.

ConsiderationsAssociated with donor-site morbidity when harvested (autologous harvest); policy prefers autograft where appropriate and supported by guidelines.

Bone Marrow Aspiration (BMA) — definition

DefinitionRemoval of liquid bone marrow tissue for use in grafting or examination.

Use as graft componentBone marrow aspirate (BMA) may be combined with graft extenders or carriers to provide osteogenic potential; policy clarifies combinations (see ceramic-based stance).

Policy noteUpdated definition and guidance added to policy (effective 12/01/2025).

Demineralized Bone Matrix (DBM) — definition

DefinitionAn allograft produced by dissolving the mineralized portion of bone and leaving the collagen matrix and retained growth factors; provides weak osteoconductive capacity and is osteoinductive; requires a carrier that serves as a more potent osteoconductive scaffold.

Common roleUsed as an extender or supplement to other graft materials in spinal fusion procedures.

Clinical noteDBM products vary by processing and carrier; product-specific evidence should be considered for coverage decisions.

InFUSE Bone Graft — definition

DefinitionInFUSE™ Bone Graft is a bone graft product that contains recombinant human bone morphogenetic protein-2 (rhBMP-2) and is approved for certain spine, dental, and trauma indications.

Manufacturer/ProductInFUSE™ (Medtronic) — rhBMP-2 on an absorbable collagen sponge carrier.

Clinical roleUsed to stimulate bone formation and avoid autologous bone harvest in indicated spine procedures when used per approved indications.

Infuse (rhBMP-2) — definition and approvals

Product descriptionInfuse (rhBMP-2) is an absorbable collagen sponge coated with recombinant human bone morphogenetic protein-2 used with an interbody fusion cage.

FDA-approved indicationApproved in the United States only for lumbosacral (L2–S1) spine fusion when used with an interbody fusion device.

Safety considerationsOff-label cervical use has been associated with life‑threatening adverse events and FDA warnings; off-label use requires strong justification.

Ceramic-based products — definition and policy stance

DefinitionCeramic-based products are mineral salts produced at high temperatures to create structures with osteoconductive properties, including hydroxyapatite, calcium phosphate, tricalcium phosphate, and calcium sulfate.

Clinical variabilityComposition, porosity, and manufacturing differences substantially affect outcomes; evidence is heterogeneous across products.

Policy stanceCeramic-based products used alone or in combination with other grafts/graft components (including BMA) are considered unproven and not medically necessary in this policy update (effective 12/01/2025).

Intra-patient design — definition

DefinitionIntra-patient design: a study design where different treatments are applied to different sides or segments within the same patient, serving as the patient's own control.

Methodologic impactThis design limits attribution of patient-reported outcomes and adverse events to a specific graft and may underestimate bilateral effects.

Use in trialsUsed in some randomized trials of ceramic substitutes; interpret results with attention to design limitations and fusion assessment methods.

Bioactive glass — definition and evidence

DefinitionBioactive glass: synthetic silica-based materials (commonly SiO2, CaO, Na2O, P2O5) purported to form hydroxyl carbonated apatite and enhance osteoconductivity and bone bonding.

Evidence statusInsufficient high‑quality evidence exists to determine efficacy and safety compared with established graft options.

Clinical claimManufacturers claim faster HCA formation and higher osteoconductivity, but comparative clinical data are limited and heterogeneous.

rhBMP-2 — definition and considerations

DefinitionrhBMP-2: recombinant human bone morphogenetic protein-2, a biologic osteoinductive agent used to promote bone formation in grafting.

Clinical considerationsAssociated with unique complications; approved uses (e.g., Infuse for L2–S1) have specific safety profiles—off-label uses (especially cervical) pose higher AE risk.

Role in fusionShown in some studies and reviews to increase fusion rates compared with plain bone substitutes, but AE rates and study heterogeneity necessitate careful use per indications.

Structural allograft — definition and indications

DefinitionStructural allograft: cortical or corticocancellous allograft bone (fresh-frozen or freeze-dried) used for structural reconstruction in spinal procedures.

IndicationsUsed for anterior cervical reconstruction (ACDF, corpectomy) and other structural uses, with or without additional autograft.

Coding/usage noteMay be billed with applicable spine procedure add-on allograft codes when indicated.

Osseointegration — definition

DefinitionOsseointegration: the stable anchorage of an implant achieved by direct bone-to-implant contact.

RelevanceKey outcome for implant fixation and long-term stability in fusion constructs and device-supported grafts.

Policy updateDefinition added to the policy effective 12/01/2025.

Osteoconduction — definition

DefinitionOsteoconduction: the process by which bone grows on a surface, providing a scaffold for new bone formation.

Clinical relevanceImportant property of graft materials and bone void fillers; many ceramic products are primarily osteoconductive.

Policy noteDefinition added to the policy effective 12/01/2025.

Osteoinduction — definition

DefinitionOsteoinduction: the process by which osteogenesis is induced through recruitment and stimulation of immature cells to develop into preosteoblasts.

Clinical relevanceMaterials with osteoinductive properties (e.g., rhBMP-2, DBM) stimulate new bone formation beyond a passive scaffold.

Policy noteDefinition added to the policy effective 12/01/2025.

Allograft / Autograft / Bone Marrow Aspiration — updated definitions

Allograft (updated)Transplant of tissue from one individual to another of the same species with a different genotype (allogeneic); clarified in policy update effective 12/01/2025.

Autograft (updated)Tissue grafted into a new position in the body of the same individual; policy reiterates autograft as preferred standard where appropriate.

Bone Marrow Aspiration (updated)Removal of liquid bone marrow tissue for use in grafting or examination; policy clarifies combinations with graft components (e.g., ceramics) and documents stance on such combinations.